Links
Organizations
Conferences
Info & Opinion
August 21, 2008
Litigation Into Perpetuity?
Drug Safety: A Lawyer’s View
A lawyer says litigation illuminates how the pharmaceutical industry thinks and conducts itself. A few forward-looking statements.
The V-Word
Merck’s Win, Industry’s Loss
The first class action settlement for Vioxx is good news for Merck but will play out differently for industry.
Three Ticking Clocks
Bayer Halts Trasylol Sales
With journal editors in charge of drug safety, the political system has failed the industry and the public.
The Case For Outreach
Stopping Drug Safety Spin Cycle
Why the pharmaceutical industry’s ill-advised reliance on lobbyists will hamper its efforts to rehabilitate its reputation.
- Home
- Tag
- vioxx
When will the drug safety wars end? How will they end? A new president? A Supreme Court decision? We thought Tom Lamb might know. He’s an attorney based in Wilmington, North Carolina. Like it or not, lawyers like Lamb are…
Earlier this month, after months of negotiations, Merck announced a large but manageable $4.85 billion settlement of an unknown number of Vioxx plaintiffs who can prove they took the drug and suffered strokes or heart attacks. Those plaintiffs still have…
In another significant win for medical journal editors in their new role as regulators, Bayer suspended sales of anti-clotting drug Trasylol (aprotinin), which had been implicated in kidney failure, cardiovascular problems and mortality risk. The drug had approximately $135 million…
A few years ago, thinking the way all journalists think, we had an epiphany. The reportorial brain is the one we’re happily stuck with. But it often adopts a harshly negative, critical outlook that transcends age, geography and political affiliation.…
We’ve been as surprised as anyone by the Wall Street Journal’s running baseball-style scorecards showing how many lawsuits Merck has won, lost and tied. It’s notable. Merck is using a starkly different strategy than the one that was popular not…
